Blog

  • SLC7A11 as a bridge between ferroptosis and disulfidptosis: a promising target for tumor treatment | Cell Communication and Signaling

    SLC7A11 as a bridge between ferroptosis and disulfidptosis: a promising target for tumor treatment | Cell Communication and Signaling

  • Newton K, Strasser A, Kayagaki N, Dixit VM. Cell death. Cell. 2024;187(2):235–56. https://doi.org/10.1016/j.cell.2023.11.044.

    Article 
    PubMed 

    Google Scholar 

  • Green DR, Victor B. The pantheon of the fallen: why are there so many forms of cell death? Trends Cell Biol. 2012;22(11):555–6. https://doi.org/10.1016/j.tcb.2012.08.008.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–72. https://doi.org/10.1016/j.cell.2012.03.042.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Bannai S, Kitamura E. Transport interaction of L-cystine and L-glutamate in human diploid fibroblasts in culture. J Biol Chem. 1980;255(6):2372–6.

    Article 
    PubMed 

    Google Scholar 

  • Fotiadis D, Kanai Y, Palacín M. The SLC3 and SLC7 families of amino acid transporters. Mol Aspects Med. 2013;34(2–3):139–58. https://doi.org/10.1016/j.mam.2012.10.007.

    Article 
    PubMed 

    Google Scholar 

  • Koppula P, Zhang Y, Zhuang L, Gan B. Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun (Lond). 2018;38(1):12. https://doi.org/10.1186/s40880-018-0288-x.

    Article 
    PubMed 

    Google Scholar 

  • Mou Y, Wang J, Wu J, He D, Zhang C, Duan C, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 2019;12(1):34. https://doi.org/10.1186/s13045-019-0720-y.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Liu J, Xia X, Huang P, xCT:. A critical molecule that links cancer metabolism to redox signaling. Mol Ther. 2020;28(11):2358–66. https://doi.org/10.1016/j.ymthe.2020.08.021.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2021;12(8):599–620. https://doi.org/10.1007/s13238-020-00789-5.

    Article 
    PubMed 

    Google Scholar 

  • Liu X, Nie L, Zhang Y, et al. Actin cytoskeleton vulnerability to disulfide stress mediates Disulfidptosis. Nat Cell Biol. 2023;25(3):404–14. https://doi.org/10.1038/s41556-023-01091-2.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Lee N, Park SJ, Lange M, et al. Selenium reduction of ubiquinone via SQOR suppresses ferroptosis. Nat Metab. 2024;6(2):343–58. https://doi.org/10.1038/s42255-024-00974-4.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22(4):266–82. https://doi.org/10.1038/s41580-020-00324-8.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Lin Q, Zhou H, Zeng J, et al. Bioactive polysaccharides mediate ferroptosis to modulate tumor immunotherapy. Int J Biol Macromol. 2024. https://doi.org/10.1016/j.ijbiomac.2024.135147.

    Article 
    PubMed 

    Google Scholar 

  • Mao C, Wang M, Zhuang L, Gan B. Metabolic cell death in cancer: ferroptosis, cuproptosis, disulfidptosis, and beyond. Protein Cell. 2024;15(9):642–60. https://doi.org/10.1093/procel/pwae003.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol. 2021;18(5):280–96. https://doi.org/10.1038/s41571-020-00462-0.

    Article 
    PubMed 

    Google Scholar 

  • Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 2021;31(2):107–25. https://doi.org/10.1038/s41422-020-00441-1.

    Article 
    PubMed 

    Google Scholar 

  • Tong X, Tang R, Xiao M, et al. Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and Cuproptosis research. J Hematol Oncol. 2022;15(1):174. https://doi.org/10.1186/s13045-022-01392-3.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Lang X, Green MD, Wang W, et al. Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov. 2019;9(12):1673–85. https://doi.org/10.1158/2159-8290.CD-19-0338.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Li Y, Yan J, Zhao Q, Zhang Y, Zhang Y. ATF3 promotes ferroptosis in sorafenib-induced cardiotoxicity by suppressing Slc7a11 expression. Front Pharmacol. 2022;13:904314. https://doi.org/10.3389/fphar.2022.904314.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Bassi MT, Gasol E, Manzoni M, et al. Identification and characterisation of human xCT that co-expresses, with 4F2 heavy chain, the amino acid transport activity system Xc-. Pflugers Arch. 2001;442(2):286–96. https://doi.org/10.1007/s004240100537.

    Article 
    PubMed 

    Google Scholar 

  • Bridges CC, Kekuda R, Wang H, et al. Structure, function, and regulation of human cystine/glutamate transporter in retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2001;42(1):47–54.

    PubMed 

    Google Scholar 

  • Kim JY, Kanai Y, Chairoungdua A, et al. Human cystine/glutamate transporter: cDNA cloning and upregulation by oxidative stress in glioma cells. Biochim Biophys Acta. 2001;1512(2):335–44.

    Article 
    PubMed 

    Google Scholar 

  • Sato H, Tamba M, Kuriyama-Matsumura K, Okuno S, Bannai S. Molecular cloning and expression of human xCT, the light chain of amino acid transport system Xc-. Antioxid Redox Signal. 2000;2(4):665–71. https://doi.org/10.1089/ars.2000.2.4-665.

    Article 
    PubMed 

    Google Scholar 

  • Li S, Lu Z, Sun R, et al. The role of SLC7A11 in cancer: friend or foe? Cancers (Basel). 2022;14(13):3059. https://doi.org/10.3390/cancers14133059.

    Article 
    PubMed 

    Google Scholar 

  • Yang J, Zhou Y, Xie S, et al. Metformin induces ferroptosis by inhibiting ufmylation of SLC7A11 in breast cancer. J Exp Clin Cancer Res. 2021;40(1):206. https://doi.org/10.1186/s13046-021-02012-7.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Badgley MA, Kremer DM, Maurer HC, et al. Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science. 2020;368(6486):85–9. https://doi.org/10.1126/science.aaw9872.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hong T, Lei G, Chen X, et al. PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer. Redox Biol. 2021;42:101928. https://doi.org/10.1016/j.redox.2021.101928.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Park JW, Kilic O, Deo M, et al. CIC reduces xCT/SLC7A11 expression and glutamate release in glioma. Acta Neuropathol Commun. 2023;11(1):13. https://doi.org/10.1186/s40478-023-01507-y.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Long Y, Tao H, Karachi A, et al. Dysregulation of glutamate transport enhances Treg function that promotes VEGF blockade resistance in glioblastoma. Cancer Res. 2020;80(3):499–509. https://doi.org/10.1158/0008-5472.CAN-19-1577.

    Article 
    PubMed 

    Google Scholar 

  • Yuan L, Li S, Chen Q, et al. EBV infection-induced GPX4 promotes chemoresistance and tumor progression in nasopharyngeal carcinoma. Cell Death Differ. 2022;29(8):1513–27. https://doi.org/10.1038/s41418-022-00939-8.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Combs JA, DeNicola GM. The non-essential amino acid cysteine becomes essential for tumor proliferation and survival. Cancers (Basel). 2019;11(5):678. https://doi.org/10.3390/cancers11050678.

    Article 
    PubMed 

    Google Scholar 

  • Carlisle AE, Lee N, Matthew-Onabanjo AN, et al. Selenium detoxification is required for cancer-cell survival. Nat Metab. 2020;2(7):603–11. https://doi.org/10.1038/s42255-020-0224-7.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Lee N, Carlisle AE, Kim D. Examining xCT-mediated selenium uptake and Selenoprotein production capacity in cells. Methods Enzymol. 2022;662:1–24. https://doi.org/10.1016/bs.mie.2021.10.002.

    Article 
    PubMed 

    Google Scholar 

  • Goji T, Takahara K, Negishi M, Katoh H. Cystine uptake through the cystine/glutamate antiporter xCT triggers glioblastoma cell death under glucose deprivation. J Biol Chem. 2017;292(48):19721–32. https://doi.org/10.1074/jbc.M117.814392.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Timmerman LA, Holton T, Yuneva M, et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013;24(4):450–65. https://doi.org/10.1016/j.ccr.2013.08.020.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Shin CS, Mishra P, Watrous JD, et al. The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility. Nat Commun. 2017;8:15074. https://doi.org/10.1038/ncomms15074.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Romero R, Sayin VI, Davidson SM, et al. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat Med. 2017;23(11):1362–8. https://doi.org/10.1038/nm.4407.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Bannai S. Induction of cystine and glutamate transport activity in human fibroblasts by diethyl maleate and other electrophilic agents. J Biol Chem. 1984;259(4):2435–40.

    Article 
    PubMed 

    Google Scholar 

  • Bannai S, Kitamura E. Adaptive enhancement of cystine and glutamate uptake in human diploid fibroblasts in culture. Biochim Biophys Acta. 1982;721(1):1–10. https://doi.org/10.1016/0167-4889(82)90017-9.

    Article 
    PubMed 

    Google Scholar 

  • Bannai S, Sato H, Ishii T, Taketani S. Enhancement of glutathione levels in mouse peritoneal macrophages by sodium arsenite, cadmium chloride and glucose/glucose oxidase. Biochim Biophys Acta. 1991;1092(2):175–9. https://doi.org/10.1016/0167-4889(91)90153-o.

    Article 
    PubMed 

    Google Scholar 

  • Pakos-Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman AM. The integrated stress response. EMBO Rep. 2016;17(10):1374–95. https://doi.org/10.15252/embr.201642195.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Ye P, Mimura J, Okada T, et al. Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition. Mol Cell Biol. 2014;34(18):3421–34. https://doi.org/10.1128/MCB.00221-14.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Ye Y, Chen A, Li L, et al. Repression of the antiporter SLC7A11/glutathione/glutathione peroxidase 4 axis drives ferroptosis of vascular smooth muscle cells to facilitate vascular calcification. Kidney Int. 2022;102(6):1259–75. https://doi.org/10.1016/j.kint.2022.07.034.

    Article 
    PubMed 

    Google Scholar 

  • Wang L, Liu Y, Du T, et al. ATF3 promotes erastin-induced ferroptosis by suppressing system Xc. Cell Death Differ. 2020;27(2):662–75. https://doi.org/10.1038/s41418-019-0380-z.

    Article 
    PubMed 

    Google Scholar 

  • Zhao X, Chen C, Qiu H, et al. The landscape of ATF3 in tumors: metabolism, expression regulation, therapy approach, and open concerns. Pharmacol Res. 2025;214:107666. https://doi.org/10.1016/j.phrs.2025.107666.

    Article 
    PubMed 

    Google Scholar 

  • Wang Y, Yang L, Zhang X, et al. Epigenetic regulation of ferroptosis by H2B monoubiquitination and p53. EMBO Rep. 2019;20(7):e47563. https://doi.org/10.15252/embr.201847563.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Zhang Y, Koppula P, Gan B. Regulation of H2A ubiquitination and SLC7A11 expression by BAP1 and PRC1. Cell Cycle. 2019;18(8):773–83. https://doi.org/10.1080/15384101.2019.1597506.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Tsuchihashi K, Okazaki S, Ohmura M, et al. The EGF receptor promotes the malignant potential of glioma by regulating amino acid transport system xc(-). Cancer Res. 2016;76(10):2954–63. https://doi.org/10.1158/0008-5472.CAN-15-2121.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Liu L, He J, Sun G, et al. The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma. Clin Transl Med. 2022;12(5):e778. https://doi.org/10.1002/ctm2.778.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Zhu Y, Zhang C, Huang M, Lin J, Fan X, Ni T. TRIM26 induces ferroptosis to inhibit hepatic stellate cell activation and mitigate liver fibrosis through mediating SLC7A11 ubiquitination. Front Cell Dev Biol. 2021;9:644901. https://doi.org/10.3389/fcell.2021.644901.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Li S, Lu Z, Sun R, et al. The role of SLC7A11 in cancer: friend or foe? Cancers (Basel). 2022;14(13):3059. https://doi.org/10.3390/cancers14133059.

    Article 
    PubMed 

    Google Scholar 

  • Ishimoto T, Nagano O, Yae T, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell. 2011;19(3):387–400. https://doi.org/10.1016/j.ccr.2011.01.038.

    Article 
    PubMed 

    Google Scholar 

  • Gan W, Dai X, Dai X, et al. LATS suppresses mTORC1 activity to directly coordinate Hippo and mTORC1 pathways in growth control. Nat Cell Biol. 2020;22(2):246–56. https://doi.org/10.1038/s41556-020-0463-6.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Zhang W, Feng J, Ni Y, et al. The role of SLC7A11 in diabetic wound healing: novel insights and new therapeutic strategies. Front Immunol. 2024;15:1467531. https://doi.org/10.3389/fimmu.2024.1467531.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Gu Y, Albuquerque CP, Braas D, et al. mTORC2 regulates amino acid metabolism in cancer by phosphorylation of the Cystine-Glutamate antiporter xCT. Mol Cell. 2017;67(1):128–e1387. https://doi.org/10.1016/j.molcel.2017.05.030.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273–85. https://doi.org/10.1016/j.cell.2017.09.021.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Doll S, Proneth B, Tyurina YY, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13(1):91–8. https://doi.org/10.1038/nchembio.2239.

    Article 
    PubMed 

    Google Scholar 

  • Kagan VE, Mao G, Qu F, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13(1):81–90. https://doi.org/10.1038/nchembio.2238.

    Article 
    PubMed 

    Google Scholar 

  • Chu B, Kon N, Chen D, et al. ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway. Nat Cell Biol. 2019;21(5):579–91. https://doi.org/10.1038/s41556-019-0305-6.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Jiang L, Kon N, Li T, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520(7545):57–62. https://doi.org/10.1038/nature14344.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Jennis M, Kung CP, Basu S, et al. An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev. 2016;30(8):918–30. https://doi.org/10.1101/gad.275891.115.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Zhang Y, Shi J, Liu X, et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol. 2018;20(10):1181–92. https://doi.org/10.1038/s41556-018-0178-0.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Liu T, Jiang L, Tavana O, Gu W. The deubiquitylase OTUB1 mediates ferroptosis via stabilization of SLC7A11. Cancer Res. 2019;79(8):1913–24. https://doi.org/10.1158/0008-5472.CAN-18-3037.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Reck M, Carbone DP, Garassino M, Barlesi F. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol. 2021;32(9):1101–10. https://doi.org/10.1016/j.annonc.2021.06.001.

    Article 
    PubMed 

    Google Scholar 

  • Xiong HJ, Yu HQ, Zhang J, et al. Elevated FBXL6 activates both wild-type KRAS and mutant KRASG12D and drives HCC tumorigenesis via the ERK/mTOR/PRELID2/ROS axis in mice. Mil Med Res. 2023;10(1):68. https://doi.org/10.1186/s40779-023-00501-8.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Mueller S, Engleitner T, Maresch R, et al. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature. 2018;554(7690):62–8. https://doi.org/10.1038/nature25459.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hu K, Li K, Lv J, et al. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma. J Clin Invest. 2020;130(4):1752–66. https://doi.org/10.1172/JCI124049.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Lim JKM, Delaidelli A, Minaker SW, et al. Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance. Proc Natl Acad Sci U S A. 2019;116(19):9433–42. https://doi.org/10.1073/pnas.1821323116.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Chen X, Li J, Kang R, Klionsky DJ, Tang D. Ferroptosis: machinery and regulation. Autophagy. 2021;17(9):2054–81. https://doi.org/10.1080/15548627.2020.1810918.

    Article 
    PubMed 

    Google Scholar 

  • Wang W, Green M, Choi JE, et al. CD8 + T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569(7755):270–4. https://doi.org/10.1038/s41586-019-1170-y.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kim DH, Kim WD, Kim SK, Moon DH, Lee SJ. TGF-β1-mediated repression of SLC7A11 drives vulnerability to GPX4 Inhibition in hepatocellular carcinoma cells. Cell Death Dis. 2020;11(5):406. https://doi.org/10.1038/s41419-020-2618-6.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Dai E, Han L, Liu J, et al. Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein. Autophagy. 2020;16(11):2069–83. https://doi.org/10.1080/15548627.2020.1714209.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Bi G, Liang J, Zhao M, et al. MiR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways. Mol Ther. 2022;28:366–86. https://doi.org/10.1016/j.omtn.2022.03.020.

    Article 

    Google Scholar 

  • Qin K, Zhang F, Wang H, et al. CircRNA circSnx12 confers cisplatin chemoresistance to ovarian cancer by inhibiting ferroptosis through a miR-194-5p/SLC7A11 axis. BMB Rep. 2023;56(2):184–9. https://doi.org/10.5483/BMBRep.2022-0175.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Sun C, Liu P, Pei L, Zhao M, Huang Y. Propofol inhibits proliferation and augments the anti-tumor effect of doxorubicin and paclitaxel partly through promoting ferroptosis in triple-negative breast cancer cells. Front Oncol. 2022;12:837974. https://doi.org/10.3389/fonc.2022.837974.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Yadav P, Sharma P, Sundaram S, Venkatraman G, Bera AK, Karunagaran D. SLC7A11/ xCT is a target of miR-5096 and its restoration partially rescues miR-5096-mediated ferroptosis and anti-tumor effects in human breast cancer cells. Cancer Lett. 2021;522:211–24. https://doi.org/10.1016/j.canlet.2021.09.033.

    Article 
    PubMed 

    Google Scholar 

  • Chen X, Kang R, Kroemer G, Tang D. Ferroptosis in infection, inflammation, and immunity. J Exp Med. 2021;218(6):e20210518. https://doi.org/10.1084/jem.20210518.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Mi T, Kong X, Chen M, Guo P, He D. Inducing disulfidptosis in tumors: potential pathways and significance. MedComm (2020). 2024;5(11):e791. https://doi.org/10.1002/mco2.791

  • Yan Y, Teng H, Hang Q, et al. Slc7a11 expression level dictates differential responses to oxidative stress in cancer cells. Nat Commun. 2023;14(1):3673. https://doi.org/10.1038/s41467-023-39401-9.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Joly JH, Delfarah A, Phung PS, Parrish S, Graham NA. A synthetic lethal drug combination mimics glucose deprivation-induced cancer cell death in the presence of glucose. J Biol Chem. 2020;295(5):1350–65. https://doi.org/10.1074/jbc.RA119.011471.

    Article 
    PubMed 

    Google Scholar 

  • Liu T, Ren Y, Wang Q, et al. Exploring the role of the disulfidptosis-related gene SLC7A11 in adrenocortical carcinoma: implications for prognosis, immune infiltration, and therapeutic strategies. Cancer Cell Int. 2023;23(1):259. https://doi.org/10.1186/s12935-023-03091-6.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Zhao D, Meng Y, Dian Y, et al. Molecular landmarks of tumor disulfidptosis across cancer types to promote disulfidptosis-target therapy. Redox Biol. 2023;68:102966. https://doi.org/10.1016/j.redox.2023.102966.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Li J, Yu T, Sun J, et al. Integrated analysis of disulfidptosis-related immune genes signature to boost the efficacy of prognostic prediction in gastric cancer. Cancer Cell Int. 2024;24(1):112. https://doi.org/10.1186/s12935-024-03294-5.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Xia Q, Yan Q, Wang Z, et al. Disulfidptosis-associated lncRNAs predict breast cancer subtypes. Sci Rep. 2023;13(1):16268. https://doi.org/10.1038/s41598-023-43414-1.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Liu L, Liu J, Lyu Q, et al. Disulfidptosis-associated lncRNAs index predicts prognosis and chemotherapy drugs sensitivity in cervical cancer. Sci Rep. 2023;13(1):12470. https://doi.org/10.1038/s41598-023-39669-3.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Korangath P, Teo WW, Sadik H, et al. Targeting glutamine metabolism in breast cancer with aminooxyacetate. Clin Cancer Res. 2015;21(14):3263–73. https://doi.org/10.1158/1078-0432.CCR-14-1200.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov. 2022;21(2):141-162. doi:10.1038/s41573-021-00339-6

  • Shao N, Qiu H, Liu J, et al. Targeting lipid metabolism of macrophages: a new strategy for tumor therapy. J Adv Res. 2025;68:99–114. https://doi.org/10.1016/j.jare.2024.02.009.

    Article 
    PubMed 

    Google Scholar 

  • Zhao X, Zhao J, Li D, et al. Akkermansia muciniphila: a potential target and pending issues for oncotherapy. Pharmacol Res. 2023;196:106916. https://doi.org/10.1016/j.phrs.2023.106916.

    Article 
    PubMed 

    Google Scholar 

  • Liu X, Zhuang L, Gan B. Disulfidptosis: disulfide stress-induced cell death. Trends Cell Biol. 2024;34(4):327–37. https://doi.org/10.1016/j.tcb.2023.07.009.

    Article 
    PubMed 

    Google Scholar 

  • Qiu H, Shao N, Liu J, et al. Amino acid metabolism in tumor: new shine in the fog? Clin Nutr. 2023;42(8):1521–30. https://doi.org/10.1016/j.clnu.2023.06.011.

    Article 
    PubMed 

    Google Scholar 

  • Liu J, Shao N, Qiu H, et al. Intestinal microbiota: A Bridge between intermittent fasting and tumors. Biomed Pharmacother. 2023;167:115484. https://doi.org/10.1016/j.biopha.2023.115484.

    Article 
    PubMed 

    Google Scholar 

Continue Reading

  • Inserting a venoarterial extracorporeal membrane oxygenation drainage cannula into the inferior vena cava through the internal jugular vein in a patient with an inferior vena cava filter | International Journal of Emergency Medicine

    Inserting a venoarterial extracorporeal membrane oxygenation drainage cannula into the inferior vena cava through the internal jugular vein in a patient with an inferior vena cava filter | International Journal of Emergency Medicine

    An 18-year-old male patient, a Moroccan international student in China, presented to the emergency department of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, with a chief complaint of persistent upper…

    Continue Reading

  • AI Helps Decode The Epigenetic ‘off-switch’ In An Ugly Plant That Lives For 3,000 Years

    AI Helps Decode The Epigenetic ‘off-switch’ In An Ugly Plant That Lives For 3,000 Years

    We all age, and for decades, science has been looking for a way to slow that clock. Much of that research is now focused on epigenetics—a system of “software” that runs on our genetic “hardware,” telling genes when to turn on and off.…

    Continue Reading

  • Sotheby’s Records Surrealist Records in Paris—and More Art News

    Sotheby’s Records Surrealist Records in Paris—and More Art News

    The Headlines

    SUSPECTED LOUVRE THIEVES ARRESTED. Two suspects have been detained in connection with the theft of jewels, including pieces once belonging to Emperor Napoleon III and Empress Eugénie, from the Louvre on October 19….

    Continue Reading

  • Arbuscular mycorrhizal fungi mediate leaf sugar profile in water-stressed trifoliate orange | BMC Plant Biology

    Arbuscular mycorrhizal fungi mediate leaf sugar profile in water-stressed trifoliate orange | BMC Plant Biology

  • Soka G, Ritchie M. Arbuscular mycorrhizal symbiosis, ecosystem processes and environmental changes in tropical soils. Appl Ecol Environ Res. 2015;13:229–45.

    Google Scholar 

  • Begum N, Qin C, Ahanger MA, Raza S,…

    • Continue Reading

  • How AI Solved a 25-Year Crohn’s Disease Mystery

    How AI Solved a 25-Year Crohn’s Disease Mystery

    The researchers then confirmed the importance of the interaction between NOD2 and girdin by comparing mouse models of Crohn’s disease lacking the girdin protein to those with girdin intact. They found that mice without girdin…

    Continue Reading

  • Trend Micro Awards Over $1,000,000 to Ethical Hackers

    Trend Micro Awards Over $1,000,000 to Ethical Hackers

    Participants at Pwn2Own Ireland discovered scores of zero-day vulnerabilities

    DALLAS, Oct. 27, 2025 /PRNewswire/ — Trend Micro Incorporated (TYO: 4704; TSE: 4704), a global cybersecurity leader, today celebrated the…

    Continue Reading

  • Clinical characteristics and prognostic analysis of concurrent Pneumocystis jirovecii pneumonia in patients with malignancies: a retrospective study | BMC Infectious Diseases

    Clinical characteristics and prognostic analysis of concurrent Pneumocystis jirovecii pneumonia in patients with malignancies: a retrospective study | BMC Infectious Diseases

    General characteristics of malignancy-PJP patients

    Fifty-six patients with an identified diagnosis of malignancy-PJP were enrolled in our study after a detailed medical record review. Thirty-four patients were male (60.7%), 22 patients were female (39.3%), and the mean age was 63 (52, 68) years. The underlying malignancies are shown in Fig. 1. Most patients had solid malignancies (45, 80.4%), and 11 (19.6%) had non-solid malignancies. According to the involved system, 23 (41.1%) patients had non-hematological malignancies, and 33 (58.9%) had hematological malignancies.

    Fig. 1

    The underlying malignancies of enrolled 56 malignancy-PJP patients. Other hematological malignancies: multiple myeloma and aplastic anemia; other non-hematological malignancies: prostate cancer, nasopharyngeal cancer, and breast cancer

    The main clinical manifestations of PJP were fever (52, 92.9%), cough (47, 83.9%), expectoration (41, 73.2%), and dyspnea (47, 83.9%). Bilateral (56, 100%), ground-glass opacities (GGOs) (48, 85.7%), and patches (45, 80.4%) were the most common chest CT manifestations. Consolidations (24, 42.9%), nodular (24, 42.9%), and pleural thickening (32, 57.1%) were observed on some chest CTs of patients with malignancy-PJP. Low peripheral CD4+ T-cell [125.0 (66.0, 207.0)/µL] counts were common in patients with malignancy-PJP.

    Some patients were complicated with other infections, such as CMV (25, 44.6%), bacterial HAP (23, 41.1%), oral candida infection (6, 10.7%), aspergillus infection (6, 10.7%), and Nocardia infection (2, 3.6%). Most patients experienced respiratory failure (47, 83.9%), approximately half of the patients needed intensive care unit (ICU) support, and 29 patients (51.8%) died.

    After PJP diagnosis, most patients (50, 89.3%) were prescribed 15 mg/kg/d trimethoprim-sulfamethoxazole (TMP-SMX). More than one-third of our patients (21, 37.5%) were also prescribed a combination of second-line anti-PJP medications, such as caspofungin, clindamycin and primaquine.

    Differences in the clinical characteristics and prognosis between PJP patients with non-hematological and hematological malignancies

    According to the involved system, the 56 patients were divided into a non-hematological malignancy group and a hematological malignancy group. The differences in clinical characteristics, laboratory test results (Table 1) and imaging findings (Table 2) between the two groups were analyzed.

    Table 1 The clinical characteristics between non-hematological malignancy-PJP group and hematological malignancy-PJP group
    Table 2 The chest CT features in non-hematological malignancy-PJP group and hematological malignancy-PJP group

    There were no significant differences in age, sex or comorbidities between the two groups. Compared with patients in the non-hematological malignancy group, more patients in the hematological malignancy group needed invasive mechanical ventilation support (60.6% vs. 43.5%, p = 0.03). Patients in the hematological malignancy group were more prone to respiratory failure and higher mortality, but the difference was not statistically significant. The time from diagnosis of oncological disease to PJP infection [72 (38.0, 112.5) days vs. 153 (92.5, 223.5) days, p < 0.01] and the time from chemotherapy to PJP infection [79.0 (46.5, 415.5) days vs. 229.0 (116.0, 677.5) days, p = 0.04] were shorter in the hematological malignancy group than in the non-hematological malignancy group. In terms of chest CT features, pleural thickening was more common in the non-hematological malignancy group than in the hematological malignancy group (73.9% vs. 45.5%, p = 0.03). However, there were no significant differences in the minimal albumin level, peripheral lymphocyte count or inflammatory marker levels between the two groups.

    Differences between the survival and non-survival groups of patients with malignancy-PJP

    The 56 patients were divided into a survival group (27 patients) and a non-survival group (29 patients) according to their clinical outcome. Compared with those in the survival group, more patients in the non-survival group were complicated with CMV (62.1% vs. 25.9%, p < 0.01) and bacterial HAP (58.6% vs. 22.2%, p < 0.01). However, there were no significant differences in clinical symptoms, chest CT features, chemotherapy before PJP infection or anti-PJP treatment between the two groups.

    In terms of laboratory test results, in the non-survival group, the peripheral lymphocyte count [0.4 (0.3, 0.7) × 109/L vs. 0.8 (0.5, 1.4) × 109/L, p < 0.01], platelet count [138.0 (74.0, 197.5) × 109/L vs. 212.0 (160.8, 265.3) × 109/L, p < 0.01], minimal albumin level [21.7 ± 5.3 g/L vs. 26.6 ± 4.6 g/L, p < 0.001], T-cell count [307.0 (151.0, 377.0)/µL vs. 447.0 (245.5, 920.5)/µL, p = 0.01) and CD4+ T-cell count [123.0 (37.0, 163.0)/µL vs. 146.0 (97.0, 417.0)/µL, p = 0.03] were significantly lower than those in the survival group. However, D-dimer [8.3 (2.0, 15.6) mg/L vs. 1.9 (0.9, 6.3) mg/L, p = 0.01], high-sensitivity C-reactive protein [107.0 (36.3, 191.3) mg/L vs. 42.2 (6.9, 87.0) mg/L, p < 0.01] and lactate dehydrogenase [588.0 (441.0, 789.5) U/L vs. 319.0 (255.0, 481.0) U/L, p < 0.01] levels were greater in the non-survival group than in the survival group.

    Prognostic analysis for patients with malignancy-PJP

    As shown in Table 3, univariate Cox regression analysis revealed that non-solid malignancies, decreased lymphocyte count, CMV viremia, bacterial HAP, and pneumomediastinum were associated with non-survival. Subsequent multivariate Cox regression analysis revealed that non-solid malignancies (HR = 2.77, χ2 = 4.83, p = 0.03, 95% CI: 1.12–6.89), CMV viremia (HR = 3.33, χ2 = 8.93, p < 0.01, 95% CI: 1.51–7.33), bacterial HAP (HR = 2.21, χ2 = 4.10, p = 0.04, 95% CI: 1.03–4.77) and pneumomediastinum (HR = 2.50, χ2 = 3.96, p < 0.05, 95% CI: 1.01–6.14) were independent risk factors associated with poor survival in patients with malignancy-PJP.

    Table 3 Univariable and multivariable Cox regression analysis of survival associated risk factors for patients with malignancy-PJP

    Kaplan‒Meier analysis (Fig. 2) was performed to explore the impact of the different types of underlying malignancies on the cumulative survival of malignancy-PJP patients. The results revealed that there was no significant difference in survival between patients with non-hematological malignancies and those with hematological malignancies. Compared with that of patients with solid malignancies, the survival rate of patients with non-solid malignancies (p < 0.05) was significantly lower.

    Fig. 2
    figure 2

    Kaplan-Meier analysis of malignancy-PJP patients on 60-day. A with hematological malignancies and with non-hematological malignancies; B with solid malignancies and with non-solid malignancies

    Continue Reading

  • 2025 U.S. Championships Long Track speed skating and World Cup Qualifier

    2025 U.S. Championships Long Track speed skating and World Cup Qualifier

    As widely expected, Olympic stars Jordan Stolz, Erin Jackson, and Cooper McLeod were the standout performers at the 2025 U.S. Long Track speed skating Championships held at the Utah Olympic Oval from 24-26 October.

    The event served as a…

    Continue Reading

  • Jon Stewart ‘Working on Staying’ at Daily Show Amid Paramount Merger

    Jon Stewart ‘Working on Staying’ at Daily Show Amid Paramount Merger

    Jon Stewart got candid about his future at “The Daily Show” at the New Yorker Festival on Sunday, telling editor David Remnick that he’s “working on staying.”

    Stewart’s current contract at Comedy Central — which is now owned…

    Continue Reading